E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prostate cancer |
Prostaat kanker |
|
E.1.1.1 | Medical condition in easily understood language |
Prostate cancer |
Prostaat kanker |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the ability to concentrate the radiotracer in the target tissue by prostatic artery injection (PAI), especially within the prostate gland compared to standard systemic intra-venous (IV) administration. |
Primaire doelstelling van deze studie is het evalueren van de mogelijkheid om de radiotracer 18F-DCFPyL PSMA te concentreren in de prostaat bij patiënten met prostaatkanker na intra-arteriële toediening in de prostaatslagaders van de tracer vergeleken met intra-veneuze toediening volgens de richtlijnen. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the PET/CT targeting characteristics of prostatic artery injection (PAI) with 18F-DCFPyL to non-target tissue; especially to the kidneys and salivary glands in comparison with IV administration .
• Correlation of 18F-DCFPyL uptake in prostatic lesions and lymph node after IV and PAI injections with standard multi-parametric MRI
Study |
Secundaire doelstelling is het evalueren van de opname van 18F-DCFPyL PSMA na intra-arteriële toediening door andere weefsels (non-target tissue), zoals de nieren en speekselklieren, in vergelijking tot de opname na intra-veneuze toediening.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age >18 years
• Confirmed histological diagnosis of PCa
• The Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Received a baseline multi-parametric MRI and 18F-DCFPyL PET scan ≤ 6 month prior to inclusion in our study done in NKI-AVL
• Demonstrate adequate hematologic and organ function, defined by the following laboratory results.
• Signed Informed Consent Form
• All (T) (N) (M) Stages |
• Ouder dan 18 jaar
• Bevestigde prostaatkanker
• The Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Baseline multi-parametric MRI and 18F-DCFPyL PET scan ≤ 6 maanden voor inclusie gedaan in NKI-AVL
• Adequate orgaan functie en hematologische waarden
• Getekend informed consent
• Alle T, N, M stadia |
|
E.4 | Principal exclusion criteria |
• History of concomitant malignancies
• Severe allergy for iodine-based contrast agents
• Prior treatments with brachytherapy or prostatectomy
• Inability to undergo intra-arterial procedure secondary to vascular abnormalities
• Body weight over 150 kg
• Severe allergy for I.V. contrast used in angiography |
• Kanker in de voorgeschiedenis
• Ernstige allergie voor iodine bevattende contrast middelen
• Eerder behandeld met brachy therapie of prostaatresectie
• Lichaamsgewicht >150kg
• Vasculaire aandoeningen die intra-arteriele toediening verhinderen
• Ernstige allergie voor contrastmiddel dat gebruikt wordt tijdens de angiografie |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Increase of the amount of tracer in the target tissue by 30% compared to systemic administration evaluated measured on PET/CT images SUV(mean and/ or max) ) compared to systemic PET. |
Een 30% verhoogde concentratie van de tracer in de prostaat op de PETC CT scan na intra-arteriële toediening van 18F-DFCPyL PSMA in de prostaatslagaders in vergelijking tot de concentratie van de tracer in de prostaat op de PET CT scan na intra-veneuze toediening. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After the PET scan with intra-arterial administration of [18F] DCFPyL |
na de PET scan waarvoor [18F] DCFPyL intra arteriaal is toegediend |
|
E.5.2 | Secondary end point(s) |
• Lower the amount of tracer in the non-target tissue, especially to the kidneys and salivary glands, by 30% compared to systemic administration evaluated via the radiation measured on PET/CT images SUV(mean and/ or max) compared to systemic PET.
• Detection of new lesions in the primary prostate tumor within the prostate gland or local lymph node identification / micro metastasis after local administration compared to standard of care systemic administration. |
Daarnaast een 30% verlaging van concentratie van de tracer in andere organen op de PET CT scan na PIA van 18F-DFCPyL in vergelijking tot na IA toediening |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After the PET scan with intra-arterial administration of [18F] DCFPyL |
na de PET scan waarvoor [18F] DCFPyL intra arteriaal is toegediend |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
intra-veneuze toediening van [18F] DCFPyL |
intra-venous administration of [18F] DCFPyL |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |